Trials / Completed
CompletedNCT03663465
The Effect of Hawthorn on Lipoprotein Cholesterol Ratio in Schizophrenics With Antipsychotics
The Disparity of Hawthorn Effects to Triglyceride/High-density Lipoprotein Cholesterol Ratio in Schizophrenics With Antipsychotics
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 135 (actual)
- Sponsor
- Calo Psychiatric Center · Academic / Other
- Sex
- All
- Age
- 16 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
Importance: The problems of side effects of metabolic disturbances in schizophrenic patients have been of worldwide concern for some time. Patients with dyslipidemia have an increased risk of cardiovascular diseases. A Chinese herb, Hawthorn, is widely used for the treatment of dyslipidemia. Objective: Therefore, this study aimed to investigate the effect of Hawthorn on lipid profile levels in schizophrenic patients treated with antipsychotics. Design, Setting, and Participants: A longitudinal case-control study was used in a general hospital in Taiwan. A total of 59 schizophrenics treated with antipsychotics, and 76 healthy adult subjects, who were all hospital workers, were enrolled in this study. Main outcomes and measures: All participants received Hawthorn at a dose of 3 gm/day for six months.
Detailed description
The problem of metabolic disturbances in schizophrenic patients who take antipsychotics has always been a cause for global concern and discussion. Although Hawthorn is widely used in the treatment of heart problems and the lowering of blood lipid levels, it is unknown whether Hawthorn has an effect in schizophrenic patients treated with antipsychotics. Hence, there are several areas of interest in the present study: 1) the effect of Hawthorn on lipid profile levels in schizophrenic patients treated with antipsychotics; 2) a comparison of lipid profile levels between schizophrenic patients and healthy adults; 3) the contributing factors that relate to changes in lipid profile levels in patients who take Hawthorn.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Hawthorn | Hawthorn tablet |
| DRUG | SGAs | SGAs tablet |
Timeline
- Start date
- 2013-01-01
- Primary completion
- 2013-12-31
- Completion
- 2014-07-31
- First posted
- 2018-09-10
- Last updated
- 2018-09-10
Source: ClinicalTrials.gov record NCT03663465. Inclusion in this directory is not an endorsement.